Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E14.46 EPS (ttm)6.22 Insider Own0.10% Shs Outstand1.59B Perf Week-5.92%
Market Cap143.11B Forward P/E10.06 EPS next Y8.94 Insider Trans-11.60% Shs Float1.59B Perf Month-8.22%
Income9.96B PEG0.90 EPS next Q1.97 Inst Own71.50% Short Float2.10% Perf Quarter-3.29%
Sales29.61B P/S4.83 EPS this Y52.60% Inst Trans0.07% Short Ratio3.96 Perf Half Y-13.35%
Book/sh2.23 P/B40.34 EPS next Y14.52% ROA9.20% Target Price113.23 Perf Year23.61%
Cash/sh5.95 P/C15.11 EPS next 5Y16.12% ROE119.30% 52W Range69.38 - 125.86 Perf YTD-6.99%
Dividend3.84 P/FCF24.96 EPS past 5Y10.60% ROI25.40% 52W High-29.71% Beta1.58
Dividend %4.27% Quick Ratio1.10 Sales past 5Y9.00% Gross Margin75.80% 52W Low27.52% ATR2.20
Employees29000 Current Ratio1.20 Sales Q/Q21.40% Oper. Margin34.00% RSI (14)29.42 Volatility2.61% 2.17%
OptionableYes Debt/Eq10.49 EPS Q/Q64.20% Profit Margin21.50% Rel Volume1.35 Prev Close89.95
ShortableYes LT Debt/Eq8.70 EarningsJul 27 BMO Payout65.90% Avg Volume8.40M Price88.47
Recom2.40 SMA20-6.28% SMA50-10.31% SMA200-11.69% Volume8,404,640 Change-1.65%
Jun-01-18Downgrade Piper Jaffray Overweight → Neutral
May-30-18Downgrade Credit Suisse Neutral → Underperform
Jan-30-18Reiterated Morgan Stanley Equal-Weight $99 → $131
Jan-29-18Downgrade Leerink Partners Outperform → Mkt Perform
Oct-30-17Reiterated Leerink Partners Outperform $108 → $107
Oct-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Sep-25-17Downgrade UBS Buy → Neutral $79 → $92
Aug-17-17Initiated Evercore ISI Outperform $95
Jun-22-17Upgrade Societe Generale Hold → Buy
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-20-18 08:59AM  Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals Zacks
08:00AM  Todays Research Reports on Stocks to Watch: eBay and AbbVie ACCESSWIRE
06:15AM  3 Top Healthcare Stocks to Buy in July Motley Fool
Jul-19-18 03:35PM  AbbVie Has Issues, But It Isn't the 'Next Big Drug Short' Bloomberg
01:53PM  Why AbbVie Shares Are Sliding Today InvestorPlace
12:12PM  How AbbVie Makes its Money Investopedia
12:03PM  AbbVie's Tumble May Not Last Barrons.com
11:58AM  AbbVie's Stock Hit By Citron Tweet Benzinga
11:17AM  3 Biotech Stocks to Watch This Quarter ACCESSWIRE
10:14AM  AbbVie shares drop 5.5% after short seller Citron calls it 'next great drug short' MarketWatch
09:45AM  Biogen (BIIB) to Report Q2 Earnings: What's in the Cards? Zacks
08:36AM  3 Big Stock Charts for Thursday: McDonalds, AbbVie and Coca-Cola InvestorPlace
Jul-18-18 02:58PM  3 'Strong Buy' Healthcare Stocks Poised to Surge TheStreet.com
01:38PM  Drugmakers Game the Patent System and Reap Billions, FDA Says Bloomberg
09:47AM  AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S. Zacks
Jul-17-18 08:46AM  Mylan signs U.S. license deal on Humira with AbbVie Reuters
08:05AM  AbbVie Announces HUMIRA® (adalimumab) Patent License with Mylan PR Newswire
Jul-15-18 06:32AM  3 Best Big Pharma Stocks to Buy for the 2nd Half of 2018 Motley Fool
Jul-13-18 09:47AM  5 Big Pharma Stocks Investors Love Right Now InvestorPlace
08:51AM  Will J&J's (JNJ) Pharma Segment Strength Drive Q2 Earnings? Zacks
08:50AM  Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit Zacks
08:16AM  2 Overlooked Biotech Stocks to Buy Now Motley Fool
Jul-12-18 06:03PM  3 Pharma Stocks Goldman Sachs Sees as Buys TheStreet.com
09:42AM  AbbVie's Imbruvica Fails in Phase III Blood Cancer Study Zacks
09:29AM  J&J (JNJ) to Set Pharma Q2 Earnings in Motion: What's Up? Zacks
08:46AM  Keep Your Eyes on Healthcare's Odd Couple: AbbVie and Alphabet Motley Fool
08:37AM  Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial Benzinga
02:00AM  [$$] The drug pricing playbook: how pharma companies keep costs high Financial Times
01:01AM  AbbVie Announces Submission of Supplemental New Drug Application to US FDA for Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy PR Newswire
Jul-11-18 07:05PM  Top 5 Biotech Stocks for 2018 Investopedia
09:23AM  Stocks to Watch: Boeing, Ford, American Airlines, JetBlue, Pfizer, Comcast, Alphabet, Nvidia, AbbVie The Wall Street Journal
08:15AM  AbbVie's stock falls after lymphoma treatment trial data disappoints MarketWatch
08:00AM  AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) and Ongoing Ibrutinib Clinical Program PR Newswire
07:05AM  Ex-Dividend Alert: AbbVie Has Raised its Dividend By 140% Since 2013; Will Trade Ex-Dividend on July 12, 2018 ACCESSWIRE
Jul-10-18 09:35AM  The Zacks Analyst Blog Highlights: Apache, Continental Resources, KMG Chemicals, ZAGG and AbbVie Zacks
08:00AM  AbbVie to Host Second-Quarter 2018 Earnings Conference Call PR Newswire
Jul-09-18 02:35PM  Celebrate Trumps 2nd Year in Office With These 5 Winners InvestorPlace
09:09AM  Better Buy: Eli Lilly and Company vs. AbbVie Motley Fool
Jul-08-18 03:54PM  5 Top Stock Trades for Monday InvestorPlace
Jul-06-18 08:01PM  3 Top Biotech Stocks to Buy in July Motley Fool
10:31AM  How Does Biogen Make its Money? Investopedia
09:15AM  3 Buy-Rated Large Cap Pharma Stocks to Boost Health in July Zacks
Jul-05-18 03:04PM  AbbVie wins reversal of $140 mln verdict in case over AndroGel risks Reuters
12:25PM  A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year Benzinga
10:36AM  Here's Why AbbVie Stock is Good for Your Portfolio's Health Zacks
07:30AM  [$$] AbbVie Director Makes Biggest-Ever Insider Stock Buy Barrons.com
07:00AM  FOCUS-Drugmakers try evasion, tougher negotiations to fight new U.S. insurer tactic Reuters
06:31AM  If You Like Dividends, You Should Love These 3 Stocks Motley Fool
Jul-03-18 10:13AM  AstraZeneca's Two New Cancer Drugs Get Approval in Japan Zacks
09:31AM  5 Great Dividend Growth Stocks to Counter Volatility Zacks
06:01AM  The 5 Biggest Blockbuster Drugs of 2024, and the Companies Poised to Profit From Them Motley Fool
Jul-02-18 04:30PM  AbbVie Is Out-Trading Its Value Why It Could Still Be Worth More Investor's Business Daily
09:02AM  Vertex's Shares Rally as a Rival's CF Candidate Disappoints Zacks
08:00AM  7 Favorite Picks of a $40 Billion Portfolio Star Investopedia
Jul-01-18 05:14PM  Insider Buys Of The Week: AbbVie, Energen, NuStar And More Benzinga
08:00AM  Pharma's 2 Biggest Setbacks in 2018 Motley Fool
Jun-30-18 05:39PM  AbbVie says it will appeal $448 million antitrust judgment MarketWatch
Jun-29-18 09:38PM  AbbVie, AndroGel partner owe $448 million in antitrust case: U.S. judge Reuters
04:52PM  Vertex Pops As Rival Disappoints In Cystic Fibrosis And AbbVie Opts Out Investor's Business Daily
03:27PM  Vertex Pharma Jumps 14% After Rival Releases Poor Cystic Fibrosis Drug Results TheStreet.com
12:19PM  Why Vertex Pharmaceuticals Incorporated Stock Surged 14% Today Motley Fool
10:53AM  Galapagos: Silver Lining to Disappointing Study Data Barrons.com
10:45AM  Bad News Delivers a Decisive Blow to Galapagos N.V. Motley Fool
09:35AM  Should Value Investors Consider AbbVie (ABBV) Stock Now? Zacks
08:11AM  Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos Benzinga
Jun-28-18 07:00AM  Healthcare: Drug Pricing Concerns Weigh on Valuations, Creating Opportunities Morningstar
Jun-27-18 11:04AM  [$$] Nike, Facebook, Mitsubishi, and Other Global Picks Barrons.com
10:02AM  AbbVie (ABBV), Calico Extend R&D Deal, to Invest $500M Each Zacks
06:01AM  3 Biotech Stocks With Major Potential Catalysts in July Motley Fool
Jun-26-18 10:54AM  Google sister company and drug giant chip in another $1 billion to cure age-related diseases CNBC
08:23AM  AbbVie shares rise on $1 bln investment in partnership with Alphabet-backed health company MarketWatch
08:00AM  AbbVie and Calico Announce Extension of Groundbreaking Collaboration PR Newswire
Jun-25-18 09:00AM  IMBRUVICA® (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer PR Newswire
08:44AM  The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, IBM, McDonald's and General Electric Zacks
07:00AM  AbbVie and Calibr announce collaboration for next generation T-cell therapies PR Newswire
Jun-24-18 06:32AM  Long-Term Investors Take Note -- These 5 Big Pharma Companies Have the Best Pipelines Motley Fool
Jun-22-18 02:32PM  Is AbbVie Inc (NYSE:ABBV) A Buy At Its Current PE Ratio? Simply Wall St.
10:53AM  Top Research Reports for Procter & Gamble, AbbVie & IBM Zacks
Jun-21-18 08:39AM  Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street Benzinga
07:28AM  Initiating Free Research Reports on Bristol-Myers Squibb and Three Other Drug Makers Equities ACCESSWIRE
Jun-20-18 08:07AM  5 Experimental New Drugs That Could Be Worth $47 Billion Motley Fool
06:01AM  Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks Motley Fool
Jun-19-18 09:21AM  8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-Annual "Week of Possibilities" PR Newswire
07:20AM  Wired News AbbVie Presents New Undetectable Minimal Residual Disease Data from Phase-3 MURANO Trial of Venetoclax with Rituximab at 23rd European Hematology Association Annual Congress ACCESSWIRE
06:32AM  3 Great Reasons to Buy Gilead Sciences Motley Fool
Jun-18-18 06:23PM  Bristol-Myers Posts Data on Empliciti, China Approves Opdivo Zacks
10:30AM  How U.S. tax reform rewards companies that shift profit to tax havens Reuters
08:20AM  Today's Research Reports on Trending Tickers: Canopy Growth and AbbVie ACCESSWIRE
Jun-17-18 12:03PM  Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming Motley Fool
Jun-15-18 10:26AM  MARKETS: Here's why stocks are dropping right now Yahoo Finance Video
09:27AM  Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals Zacks
09:01AM  3 High-Yield Stocks at Rock-Bottom Prices Motley Fool
08:18AM  Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc Motley Fool
07:35AM  Analysis: Positioning to Benefit within Canopy Growth, Aurora Cannabis, CannTrust, AbbVie, Cronos Group, and Scotts Miracle-Gro Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
02:45AM  AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress PR Newswire
Jun-14-18 06:52PM  AbbVie Declares Quarterly Dividend PR Newswire
Jun-13-18 06:01AM  Humira's Sales Will Decline -- and It's Fantastic News for AbbVie Motley Fool
Jun-12-18 06:38PM  AbbVie Presents Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018) PR Newswire
Jun-11-18 10:00AM  Abbvie/Roche's Leukemia Drugs Combination Gets FDA Approval Zacks
09:37AM  JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space Zacks
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection for autoimmune diseases; IMBRUVICA, an oral therapy for patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. It serves wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has a collaboration with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; International Myeloma Foundation; Calibr and Scripps Research; The Institute for Research in Immunology and Cancer ? Commercialization of Research; and the Universite de Montreal. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TILTON GLENN FDirectorJun 27Buy91.905,400496,27439,735Jun 29 02:30 PM
RAPP EDWARD JDirectorJun 20Buy98.631,01399,90920,743Jun 22 05:56 PM
ALBAN CARLOSEVP, Commercial OperationsMar 01Option Exercise29.2348,1001,405,795178,547Mar 02 05:29 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 01Option Exercise25.9132,400839,339197,263Mar 02 05:28 PM
Schumacher Laura JExecutive Vice PresidentMar 01Sale117.8525,0002,946,14898,317Mar 02 05:28 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 01Sale114.5032,4003,709,687164,863Mar 02 05:28 PM
ALBAN CARLOSEVP, Commercial OperationsMar 01Sale114.3980,9959,264,80897,552Mar 02 05:29 PM
Michael Robert A.VP, ControllerFeb 28Sale119.434,294512,8536,876Mar 02 05:31 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 28Sale117.771,337157,45893,312Mar 02 05:31 PM
SEVERINO MICHAELEVP, R&D and CSOFeb 28Sale117.932,643311,684132,281Mar 02 05:30 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 28Sale118.6718,1292,151,45217,588Mar 02 05:30 PM
CHASE WILLIAM JEVP, Chief Financial OfficerFeb 28Sale119.4438,5284,601,954164,863Mar 02 05:28 PM
ALBAN CARLOSEVP, Commercial OperationsFeb 28Sale117.852,579303,928130,447Mar 02 05:29 PM
GONZALEZ RICHARD AChairman of the Board and CEOFeb 28Sale117.888,280976,084313,012Mar 02 05:28 PM
Michael Robert A.VP, ControllerFeb 20Sale120.31992119,35113,557Feb 20 06:08 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesDec 18Option Exercise35.8887,0403,122,995113,118Dec 19 06:09 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesDec 18Sale98.4587,0408,569,05326,078Dec 19 06:09 PM
Schumacher Laura JExecutive Vice PresidentDec 15Option Exercise35.881,14341,011106,875Dec 15 05:13 PM
Schumacher Laura JExecutive Vice PresidentDec 14Option Exercise35.88144,3675,179,888250,099Dec 15 05:13 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 21Option Exercise58.88218,19312,847,204492,030Nov 24 04:55 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 21Sale94.01218,19320,511,800273,837Nov 24 04:55 PM
SEVERINO MICHAELEVP, R&D and CSONov 10Sale94.6925,6332,427,212114,922Nov 13 05:26 PM
Gosebruch Henry OChief Strategy OfficerOct 30Sale90.5518,3001,657,03765,137Oct 31 05:04 PM
Michael Robert A.VP, ControllerSep 28Sale88.006,699589,51210,007Sep 29 05:02 PM
SALEKI-GERHARDT AZITASVP, OperationsSep 11Option Exercise24.214,800116,19993,099Sep 12 05:40 PM
SALEKI-GERHARDT AZITASVP, OperationsSep 11Sale85.028,300705,65584,799Sep 12 05:40 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 07Option Exercise51.42193,1319,930,796469,623Aug 08 07:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 07Sale71.00193,13113,713,186276,492Aug 08 07:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 04Option Exercise51.4222,0381,133,194364,391Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 04Sale71.0722,0381,566,166276,492Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 03Option Exercise51.4265,8613,386,573342,353Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 03Sale71.0065,8614,676,131298,530Aug 04 05:01 PM
RAPP EDWARD JDirectorJul 31Buy70.454,000281,78215,498Aug 02 05:05 PM
Gosebruch Henry OChief Strategy OfficerJul 31Sale70.0918,0001,261,63883,737Aug 02 05:05 PM
Gosebruch Henry OChief Strategy OfficerJul 31Sale70.4230021,12783,437Aug 02 05:06 PM